

1642
Docket Number: 037003-0280727

PATENT APPLICATION

Client Reference: 2001-30-0080CP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of

GARY R. BRASLAWSKY et al.

Group Art Unit: 1642

Application No.: 10/058,069

Examiner: Unassigned

Filed: January 29, 2002

Confirmation No.: 2502

For: ENGINEERED TETRAVALENT ANTIBODIES AND METHODS OF USE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. The attached references were cited in U.S. and international/foreign patent applications related to the present application. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

Respectfully Submitted,



Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: October 29, 2003
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102



FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	037003-0280727	2001-30-0080CP1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Braslawsky, et al.

Appln. No.: 10/058,069

Filing Date: January 29, 2002

Date: October 29, 2003

Page

1

of

12

Examiner: TBA

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	5,435,990	07/1995	Cheng, et al.	424	153	
	BR	5,512,443	04/1996	Schlom, et al.	435	7.23	
	CR	5,756,065	05/1998	Wilson, et al.	424	1.53	
	DR	5,877,291	03/1999	Mezes, et al.	530	387.3	
	ER	5,891,996	04/1999	Mateo de Acosta del Rio, et al.	530	387.3	
	FR	5,892,019	04/1999	Schlom, et al.	536	23.53	
	GR	5,892,020	04/1999	Mezes, et al.	536	23.53	
	HR	5,976,531	11/1999	Mezes, et al.	424	133.1	
	IR	5,993,813	11/1999	Mezes, et al.	424	133.1	
	JR	6,051,225	04/2000	Mezes, et al.	424	133.1	
	KR	6,103,889	08/2000	Whitlow, et al.	536	23.53	
	LR	6,121,022	09/2000	Presta, et al.	435	69.7	
	MR	6,165,745	12/2000	Ward, et al.	435	69.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
	NR	0 365 997 B1	09/1994	EP	Mezes, et al.				
	OR	0 394 277 B1	01/1998	EP	Schlom, et al.				
	PR	0 327 378 B1		EP	Morrison et al.				
	QR	WO 00/26394	05/2000	PCT	Kashmiri, et al.				
	RR	WO 89/01783	02/1989	PCT	Bodmer, et al.				
	SR	WO 97/11370	03/1997	PCT	Leung, et al.				
	TR	WO 99/43816	09/1999	PCT	Anderson, et al.				
	UR	WO 95 09917	04/1995	PCT	Univ. of CA				
	VR	WO 98 05787	02/1998	PCT	Squibb Bristol Myers Co.				
	WR	WO 99 36105	07/1999	PCT	MCA Dev BV; Vriesendorp Huibert M				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	XR	Goel et al., Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application, (2000), <i>Cancer Research</i> , 60:6964-6971.
	YR	Jiang et al., Enhanced effector functions of dimeric forms of IDEC -C2B8 (Rituximab), 1999, <i>Blood</i> , 94(10):86A (Abstract).
	ZR	Slavin-Chiorini et al., A CDR-grafted (humanized) domain-deleted antitumor antibody, (1997), <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 5(12):305-316.

OCT 29 2003

PATENT & TRADEMARK OFFICE

	AAR	Slavin-Chiorini et al., Immunological properties of chimeric domain-deleted anticarcinoma immunoglobulins, (1995), <i>Cancer Research</i> , 55:5957-5967.
	BBR	Coloma et al., Design and production of novel tetravalent bispecific antibodies, (1997), <i>Nature Biotechnology</i> , 15(2):159-163.
	CCR	Ghetie et al., Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells, (1997), <i>PNAS of USA</i> , 94:7509-7514.
	DDR	International Search Report dated April 11, 2003, for PCT Application PCT/US02/02373
Examiner		Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		